The following criteria is provided for health care professionals.

Inclusion Criteria:

• Must have relapsed or refractory multiple myeloma (RRMM) after having received prior lines of anti-myeloma treatments, including being refractory to a proteasome inhibitor, immunomodulatory agent and an anti-CD38 monoclonal antibody
• Measurable disease as defined by one of the following: abnormal serum or M-protein levels; abnormal serum free light chain (FLC) assay; ≥ 30% clonal plasma cells in the bone marrow aspirate or biopsy sample
• Pulse oximetry ≥ 92% on room air
• Eastern Cooperative Oncology Group (ECOG) performance of 0 - 2
• Be willing and able to comply with the study schedule and all study requirements
• Willing to follow contraception guidelines

Exclusion Criteria:

• Prior systemic anti-tumor therapy or an investigational drug within 5 half-lives or 4 weeks of D1, whichever is shorter, preceding the first dose of study drug
• Prior treatment with allogeneic hematopoietic stem cell transplantation within 6 months, has active graft versus host disease following transplant or currently receiving immunosuppressive therapy following transplant
• Diagnosis of other malignancies if the malignancy required therapy in the last 3 years or is not in complete remission
• Current history of CTCAE Grade 3 muscle paresis or ocular disorders that are Grade 3 or 2
• Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening
• Abnormal INR or aPTT, unless on a stable dose of an anticoagulant
• Has ≥ Grade 3 neuropathy or Grade 2 neuropathy with associated pain
• Has any clinically significant baseline lab results for creatinine clearance, serum aspartate aminotransferase, alanine aminotransferase, total bilirubin
• New York Heart Association Class > 2
• Left ventricular ejection fraction < 40%
• Prolonged QTcF interval on a 12-lead electrocardiogram
• Has active COVID-19 infection, and not present with symptoms within 4 weeks of study drug
• Has an active bacterial, viral, or fungal infection
• Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C
• Is currently pregnant or breast feeding or planning on either during the study
• Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation
• Has any additional clinical history that would place the patient at an unacceptable risk if the patient participates in the study